Bellevue Group Ag Apellis Pharmaceuticals, Inc. Transaction History

Bellevue Group Ag

$5.93 Billion
Q3 2024

A detailed history of Bellevue Group Ag transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bellevue Group Ag holds 19,046 shares of APLS stock, worth $631,184. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,046

Previous 444,404 95.71%

Holding current value

$631,184

Previous $17 Million 96.78%

% of portfolio

0.01%

Previous 0.29%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $12.3 Million - $17.5 Million	-425,358 Reduced 95.71%	19,046 $549,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $1.12 Million - $1.76 Million	-29,511 Reduced 6.23%	444,404 $17 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $19.3 Million - $25.2 Million	-347,885 Reduced 42.33%	473,915 $27.9 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $1.04 Million - $1.81 Million	27,959 Added 3.52%	821,800 $49.2 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $6.51 Million - $24.6 Million	275,346 Added 53.1%	793,841 $30.2 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $45.3 Million - $55.1 Million	-590,887 Reduced 53.26%	518,495 $47.2 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $240,637 - $345,848	5,165 Added 0.47%	1,109,382 $73.2 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $4.18 Million - $5.91 Million	96,773 Added 9.61%	1,104,217 $57.1 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $8.91 Million - $13.9 Million	-198,978 Reduced 16.49%	1,007,444 $68.8 Million
Q2 2022 Aug 11, 2022	BUY	$35.07 - $59.21 $3.78 Million - $6.38 Million	107,710 Added 9.8%	1,206,422 $54.6 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $15.9 Million - $24.3 Million	448,121 Added 68.88%	1,098,712 $55.8 Million
Q4 2021 Feb 10, 2022	BUY	$30.74 - $49.16 $18.5 Million - $29.6 Million	602,591 Added 1255.4%	650,591 $30.8 Million
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $1.48 Million - $2.75 Million	48,000 New	48,000 $2.75 Million
Q2 2020 Aug 13, 2020	SELL	$24.8 - $38.49 $741,520 - $1.15 Million	-29,900 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $535,509 - $1.33 Million	29,900 New	29,900 $801,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Apellis Pharmaceuticals, Inc. Transaction History